Q-omics provides the consensus-scored TRIM63 profile across patient tissues and cancer cell-line models. TRIM63 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TRIM63 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TRIM63 RNA expression shows 14,546 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight CESC, and HNSC as cancer lineages where TRIM63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM63 survival associations across molecular data types. TRIM63 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM63 RNA expression–survival associations across cancer types. High TRIM63 expression shows unfavorable associations in SCLC, HNSC, UCEC and SKCM, but favorable associations in CESC and KIRP. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TRIM63 RNA expression.
This table summarizes TRIM63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM63 shows lower tumor expression in HNSC, LUAD, BLCA, COAD and UCEC and higher tumor expression in THCA. The HNSC box plot shows higher TRIM63 RNA expression in normal versus tumor tissue (log2 FC = −1.787, t-test p = .006).
This table shows molecular features associated with TRIM63 in patient tissues and cancer cell lines. In patient samples, TRIM63 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM63 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
